The updated phase I clinical trial is designed to determine the safety, tolerability and immunogenicity of the extended schedule vaccination with MVA-EBNA1/LMP2 in EBV+ NPC patients [NCT01800071]. Here, PSMB9 is linked to nasopharyngeal carcinoma.